TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Modulation of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Occurrence of solicited adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: 15-Dimensions Health-Related Quality of Life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diagnosis of liver cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: self-care behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: adaptation to illness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: knowledge level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent Change in Insulin Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Baseline corrected area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone density around femoral component implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Detectable C-Reactive Protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VAS Foot and Ankle Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAAM Sports Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive outcome measured by ALP and AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loco-regional control at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute toxicity requiring an interruption of radiotherapy for more than 2 weeks
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients diagnosed with severe pneumonia within 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Change in Chronic Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Location
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neuropathic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in PANSS negative factor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Toxicity/Side Effects of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton Scale for Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cambridge Neuropsychological Test Automated Battery (CANTAB)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: myocardial deformation indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Plaque Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Plaque Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast wash-in time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in use of analgesic meds after 6 weeks of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in 50 ft. walk and 4 step up/down climb time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-Year Restricted Mean Survival Time for Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Parkinson signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of tremor (rest and postural)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: induction ease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: emergence ease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Correlation of RNAseq-based peripheral blood assay with liver biopsy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of acid reflux episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FIT Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in California Verbal Learning Test-II
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of adhesion to ventral abdominal wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CK-MB mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COPD Self Efficacy Scale (CSES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Efficacy for Managing Shortness of Breath (SEMSOB)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SGRQ HKC Total
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of pulmonary disease risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pharmacodynamic Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the common femoral artery's blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of lower extremities muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of general health status (SF-12 score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of periprosthetic femoral fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Change of Mini Mental State Examination (MMSE) test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of Adenbrooke's Cognitive Exam (ACE) test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change of Neuropsychiatric Inventory Questionnaire (NPI-Q) score result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Severity of Nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Severity of Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pharmacokinetics of Leucovorin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical performance in HoLEP procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time of Second Stage of Labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sign and symptoms composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mouth dryness severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thirst severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saliva PH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device discontinuation rate due to skin toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Localization of occult endometriotic lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: performance of vaginal fluid test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: performance of amniocentesis test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence rate of lung cancer
Endpoint domain: Mortality/survival
Primary endpoint: Number of Responders (Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 1 Genitourinary Events or Higher
Endpoint domain: Adverse events/effects
Primary endpoint: number of adipocytes and preadipocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Target site revascularization or restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 Months Progression-free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Complication events
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in wall measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Tumor Mutational Burden (bTMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean percent of applicable Guideline Advantage standards of care met
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale of pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pulmonary side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in neck pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chair Sit and Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of Cortisol Level in Saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: State-Trait Anxiety Inventory (STAI I-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pull test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stent restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Tinnitus Handicap Inventory (THI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with Covid-19 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with Influenza H1N1 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with Influenza A infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with Influenza B infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in GIP release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in GLP-1 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in GLP-2 release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in PYY release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in insulin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in combined blood levels of glucose and insulin, expressed in calculated indices for insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Boston Carpal Tunnel Questionnaire Symptom Severity Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary patency of the treated site at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: edoxaban peak plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viscoelastic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cochlear Microphonic Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of pH strips
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinical Symptom Score at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum C-reactive protein at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duplex Ultrasound volume flow values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: changes in patient-reported cognitive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of Participants with Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in functional brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite appetite score area under the curve (180 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC) from 0 to last time point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous Cocaine Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Betamethasone Dipropionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of Betamethasone Dipropionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Calcipotriol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depressive Symptoms Based on BDI-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Depressive Symptoms Based on CDRS-R
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of episodes of breech in safety thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of compliance to protocol
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in stool poliovirus excretion after mOPV2 challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion and seroprotection to type 1, 2 and 3 poliovirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 24-h pH-impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IKDC Knee Form 2000 Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Activity of temozolomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 17-hydroxyprogesterone response to ACTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average major-symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hurley Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Decrease from Baseline in Mean Hourly Heart Rate (Emax HR) on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Decrease from Baseline in Mean Hourly Heart Rate (Emax HR) on Day 19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimum of the Mean Hourly HR for each day (HR nadir) on Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Minimum of the Mean Hourly HR for each day (HR nadir) on Day 19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events including injection-site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiac rhythm monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in treatment outcome evaluation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease from baseline in alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease from baseline in alcohol use severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in psychiatric symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Neurocognitive Index (NCI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in Wisconsin Brief Pain Inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Visual Acuity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of specific IgE antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mechanical pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the ODS score (ODS-S)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of treatment naive LARC patients with circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in circulating tumor cells status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vertical Jump Height Immediately Post Tape Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unilateral Three Hop for Distance Immediately Post Tape Administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DLT evaluation for safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: ORR for efficacy
Endpoint domain: Physiological/clinical
Primary endpoint: Number of pediatric cancer patients undergoing ovarian tissue cryopreservation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: elevated systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of hepatic necroinflammation and fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Weight reference centiles for preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of Chronic Shoulder Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in maximal oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in peak treadmill velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in running velocities at the 1st and the 2nd lactate thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in critical velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Mean End-of-Day Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Anemia
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients receiving transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Active knee extension score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Existence of cardiac activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of respiratory movements and/or gasps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Existence of limb movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative change in fibrofatty component of plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immunomodulating effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from clinically driven Target Lesion Revascularization (TLR)
Endpoint domain: Adverse events/effects
Primary endpoint: Post operative pain measured by FLACC Pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative pain measured by Wong-Baker Faces pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Mepolizumab for Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration Time Curve to Infinity (AUC [0-inf]) of Mepolizumab for Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Phase Elimination Half-life (T1/2) of Mepolizumab During Treatment Period for Part A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes